Ticker

Palatin Technologies (NYSEAMERICAN:PTN) executives highlighted recent financing activity, progress in the company's melanocortin-4 receptor (MC4R)-based obesity pipeline, and updated financial results during the company's second quarter fiscal 2026 earnings call. Financing strengthens balance sheet and restores NYSE American compliance Chief Financial Officer and Chief Operating Officer Steve Wills said the company…

Palatin Technologies, Inc. (PTN) Q2 2026 Earnings Call Transcript

Advancing differentiated MC4R-based obesity programs into clinical development Melanocortin-based obesity therapies targeting rare MC4R pathway disorders with a primary focus on hypothalamic obesity and Prader-Willi syndrome Oral small-molecule MC4R agonist PL7737 progressing through IND-enabling toxicology studies, with IND submission and clinical trial initiation planned for the first half of 2026 Next-generation…

Palatin Technologies shares rose in after-hours trading as Janus Henderson Group and its subsidiary reported shared ownership of the company's stock.

Pre-Market Stock Futures: The futures are trading higher on Wednesday after a stellar day across Wall Street on Tuesday. All of the major indices finished the day higher, with the technology-heavy NASDAQ leading the way, closing up 0.59% at 23,413. The S&P 500 ended the session at 6,829, up 0.25% and the Dow Jones Industrials... Here Are Wednesday's Top Wall Street Analyst Upgrades and Downgrades: American Eagle…